Heartflow Inc. Reports Preliminary Q2 2025 Revenue of $43.4 Million, Exceeds Initial Forecast; Gross Margin at 75.5%

Reuters
2025/09/10
Heartflow Inc. Reports Preliminary <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue of $43.4 Million, Exceeds Initial Forecast; Gross Margin at 75.5%

Heartflow Inc. has released preliminary unaudited financial results for the three months ended June 30, 2025. The company reported revenue of approximately $43.4 million. The gross margin for this period is expected to be around 75.5%. Operating expenses are anticipated to be approximately $46.5 million. As of June 30, 2025, Heartflow's cash and cash equivalents stood at approximately $80.2 million. This figure does not include the net proceeds of about $333.0 million from the company's initial public offering completed on August 11, 2025. Additionally, during the three months ending September 30, 2025, the company plans to fully repay all amounts outstanding under its Credit Agreement and Guaranty with Hayfin Services LLP, which totaled $114.1 million as of June 30, 2025, plus accrued interest and related fees. Heartflow has also published an Investor Presentation on its website in connection with its participation at the Morgan Stanley 23rdAnnual Global Healthcare Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001464521-25-000009), on September 10, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10